Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC By Ogkologos - July 9, 2025 778 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SERENA-6 study Source RELATED ARTICLESMORE FROM AUTHOR Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk Patients Identified Through ctDNA-based MRD Assessment After CRC Resection ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems MOST POPULAR Treatment in Breast Cancer Patients Over 70 May Be Safely Reduced April 21, 2021 Study Clarifies Timing of Immunotherapy for Advanced Bladder Cancer June 24, 2020 Determining Fluid Requirements March 26, 2021 Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual TNBC Following Neoadjuvant... June 18, 2021 Load more HOT NEWS Addressing Cancer Pain with Complementary Methods (Part 1) EMA Recommends Granting a Marketing Authorisation for Celdoxome Pegylated Liposomal Stage IV Cancer Patient Clinging to Life Overseas While Family Raises... FDA Approves Liquid Biopsy NGS Companion Diagnostic Test for Multiple Cancers...
